Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry

Kampen, Roel J.W. van; Canals, Carmen; Schouten, Harry C.; Nagler, Arnon; Thomson, Kirsty; Vernant, Jean Paul; Buzyn, Agnès; Boogaerts, Marc; Luan, Jian Jian; Maury, Sébastien; Milpied, Noël; Jouet, Jean Pierre; Ossenkoppele, Gert J.; Sureda, Anna

doi:10.1200/jco.2010.30.2596

Cited by 198 publications

(168 citation statements)

References 33 publications

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

“…16,17,[25][26][27][28] The majority of the studies conclude that MAC allo-HCT is effective as salvage treatment in only a small subset of 'younger patients' with relapsed DLBCL. However, its association with both a high TRM and relapse rates results in a survival benefit for only 25% of these patients.…”

Section: Allo-hct With Myeloablative Conditioning Regimenmentioning

confidence: 99%

“…28 MAC regimens were used in 37 patients and consisted of TBI-based regimen in 54% of patients. The use of MAC regimens was associated with a trend to higher NRM and lower relapse rates compared with reducedintensity conditioning (RIC) regimens with no differences in PFS and OS.…”

Section: Allo-hct In Dlbcl Patients Sg Papageorgiou Et Almentioning

confidence: 99%

“…This allowed the extension of allo-HCT to older patients or those with comorbidities and patients whose disease had progressed or relapsed after auto-HCT. 30,31 Although an early EBMT registry study reported disappointing outcomes for patients with high-grade NHL who underwent RIC allo-HCT with high rates of relapse (79% at 2 years), 32 recent trials in DLBCL have demonstrated the efficacy of this approach mainly in patients with chemosensitive disease 23,28,[32][33][34][35][36] (Table 2).…”

Section: Allo-hct With Non-myeloablative or Ricmentioning

confidence: 99%

“…Finally, van Kampen et al 28 reported the results of 64 DLBCL patients (median age of 54 years) who relapsed after auto-HCT and subsequently underwent RIC allo-HCT. The conditioning regimen consisted of fludarabine-based combinations in 86% of patients.…”

Section: Allo-hct With Non-myeloablative or Ricmentioning

confidence: 99%

See 3 more Smart Citations

The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL)

Papageorgiou

Cwynarski

Kottaridis

2013

Bone Marrow Transplant

View full text Add to dashboard Cite

Despite the undoubted improvement in the prognosis of patients with diffuse large B-cell lymphomas (DLBCLs) with the addition of rituximab in the front-line treatment, a significant proportion of patients still relapse. Salvage immune-chemotherapy followed by high-dose therapy with autologous haematopoietic cell transplantation (auto-HCT) remains the treatment of choice for such patients, especially in those who demonstrate chemosensitive disease. In recent years, allogeneic haematopoietic cell transplantation (allo-HCT) has increasingly been used for patients who are resistant to salvage treatment or relapse after an auto-HCT. Strategies using reduced intensity conditioning regimens have allowed application of this approach to a broader range of patients. PFS is up to 55% with a risk of relapse up to 80% depending on different studies. In multivariate analysis, several factors have been associated with favourable outcome including chemosensitivity of the disease, younger age and Karnofsky performance status at the time of the transplant being the strongest ones. DLIs have shown to induce durable responses in relapsed or progressed disease; however, its role remains controversial as the results are inferior to the responses seen in other haematological malignancies. More recently, the addition of MoAbs in the non-myeloablative conditioning regimens has shown encouraging results. In conclusion, allo-HCT is a feasible option in selective patients with chemosensitive DBCL, as it reduces the risk of relapse; however, this is achieved at the cost of significant non-relapse mortality.

show abstract

Section: Allo-hct With Myeloablative Conditioning Regimenmentioning

confidence: 99%

Section: Allo-hct In Dlbcl Patients Sg Papageorgiou Et Almentioning

confidence: 99%

Section: Allo-hct With Non-myeloablative or Ricmentioning

confidence: 99%

Section: Allo-hct With Non-myeloablative or Ricmentioning

confidence: 99%

See 2 more Smart Citations

The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL)

Papageorgiou

Cwynarski

Kottaridis

2013

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Allografting is slowly gaining ground, with ever more patients failing other approaches being referred to this, still rather drastic, treatment method [23]. However, the exact place and importance of allografting in treatment of DLBCL patients as well as the up and down sides of reduced intensity conditioning remain to be discerned in the decades to come.…”

Section: Diffuse Large B-cell Lymphoma (Dlbcl)mentioning

confidence: 99%

Changing therapeutic landscape – The last decade

Aurer

2011

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Registry Data and Conditioning Therapy for Allogeneic Hematopoietic Cell Transplant and Lymphoma

2020

View full text Add to dashboard Cite

show abstract

Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry

Abstract: Allo-SCT in relapsed DLBCL after ASCT is a promising therapeutic modality. Patients with a long remission after ASCT and with sensitive disease at allo-SCT are the best candidates for this approach.

Cited by 198 publications

References 33 publications

The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL)

The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL)

Changing therapeutic landscape – The last decade

Registry Data and Conditioning Therapy for Allogeneic Hematopoietic Cell Transplant and Lymphoma

Contact Info

Product

Resources

About